We are proud that such a transformative treatment for SMA will be available to these infants." "Evrysdi treatment allowed almost all of the babies to achieve developmental milestones in a similar timeframe as infants who don't have SMA. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics. "The label extension for Evrysdi to include pre-symptomatic infants is the critical next step for intervening as early as possible in treating babies with SMA," said Stuart W. Food and Drug Administration (FDA) has approved a label extension for Evrysdi ® (risdiplam) to include infants under 2 months old with spinal muscular atrophy (SMA). (NASDAQ: PTCT) today announced that the U.S. SOUTH PLAINFIELD, N.J., /PRNewswire/ - PTC Therapeutics, Inc. Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date. Evrysdi is the first and only at-home administered treatment for patients living with SMA.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |